{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T21:57:06Z","timestamp":1768773426856,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ijcard.2018.03.093","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T18:38:34Z","timestamp":1533580714000},"page":"169-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Effect of sacubitril\/valsartan on cardiac filling pressures in patients with left ventricular systolic dysfunction"],"prefix":"10.1016","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0451-9155","authenticated-orcid":false,"given":"Zubair","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunjan","family":"Gholkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1443-2387","authenticated-orcid":false,"given":"Sunit","family":"Tolia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman","family":"Kado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Zughaib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2018.03.093_bb0005","first-page":"e38","article-title":"Heart disease and stroke statistics-2016 update a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0010","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1161\/CIR.0b013e31820a55f5","article-title":"Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association","volume":"123","author":"Heidenreich","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0015","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0020","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0025","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013Neprilysin inhibition versus Enalapril in Heart Failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cardfail.2017.10.011","article-title":"Should hemodynamic guidance for treatment of acute decompensated heart failure be driven by the right?","volume":"24","author":"Franciosa","year":"2018","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0035","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0735-1097(01)01229-3","article-title":"A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients","volume":"37","author":"Khalil","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0040","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0045","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0050","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","article-title":"Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial","volume":"377","author":"Abraham","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0055","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0002-8703(85)90167-X","article-title":"A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response","volume":"110","author":"Chatterjee","year":"1985","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0060","doi-asserted-by":"crossref","first-page":"36A","DOI":"10.1016\/0002-9149(85)90794-5","article-title":"Clinical and hemodynamic experience with enalapril in congestive heart failure","volume":"55","author":"Cody","year":"1985","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0167-5273(86)90197-X","article-title":"Enalapril in congestive heart failure: acute and chronic invasive hemodynamic evaluation","volume":"11","author":"Gomez","year":"1986","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0070","doi-asserted-by":"crossref","first-page":"164D","DOI":"10.1016\/0002-9149(87)90072-5","article-title":"Acute hemodynamic and hormonal effects of ramipril in chronic congestive heart failure and comparison with captopril","volume":"59","author":"de Graeff","year":"1987","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0075","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/0002-8703(88)90621-7","article-title":"Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses","volume":"116","author":"Uretsky","year":"1988","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0080","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S0735-1097(84)80292-2","article-title":"Hemodynamic effects of vasodilators and long-term response in heart failure","volume":"3","author":"Franciosa","year":"1984","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0085","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0002-9149(89)90900-4","article-title":"Hemodynamic effects of lisinopril after long-term administration in congestive heart failure","volume":"63","author":"Stone","year":"1989","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0090","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.88.4.1602","article-title":"Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure","volume":"88","author":"Gottlieb","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0095","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/01.CIR.91.3.691","article-title":"Losartan in heart failure: hemodynamic effects and tolerability","volume":"91","author":"Crozier","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0100","first-page":"III175","article-title":"Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness","volume":"73","author":"Colucci","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0105","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1388-9842(01)00202-1","article-title":"Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure","volume":"4","author":"Shah","year":"2002","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0110","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/01.CIR.69.6.1135","article-title":"Lack of relationship between the short-term hemodynamic effects of captopril and subsequent clinical responses","volume":"69","author":"Massie","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0115","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ejheart.2004.07.013","article-title":"Echo-Doppler and clinical evaluations to define hemodynamic profile in patients with chronic heart failure: accuracy and influence on therapeutic management","volume":"7","author":"Capomolla","year":"2005","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0120","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1056\/NEJMoa1010029","article-title":"Telemonitoring in patients with heart failure","volume":"363","author":"Chaudhry","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0125","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.111.018473","article-title":"Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study","volume":"123","author":"Koehler","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0130","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1001\/jamainternmed.2015.7712","article-title":"Effectiveness of remote patient monitoring after discharge of hospitalized patients with heart failure","volume":"176","author":"Ong","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0135","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","article-title":"Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association","volume":"135","author":"Chow","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0140","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.jacc.2007.06.061","article-title":"Comparison of a radiofrequency-based wireless pressure sensor to Swan\u2013Ganz catheter and echocardiography for ambulatory assessment of pulmonary artery pressure in heart failure","volume":"50","author":"Verdejo","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0145","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(15)00723-0","article-title":"Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial","volume":"387","author":"Abraham","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0150","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/j.crvasa.2013.03.010","article-title":"Natriuretic peptides-physiology, pathophysiology and clinical use in heart failure","volume":"55","author":"Krupicka","year":"2013","journal-title":"Cor Vasa"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0155","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0160","unstructured":"Ongoing clinical trials sacubitril\/valsartan - ClinicalTrials.gov (https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=sacubitril%2Fvalsartan&cntry1=&state1=&recrs=#tableTop)."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0165","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1161\/01.CIR.99.20.2658","article-title":"Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure","volume":"99","author":"Baruch","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0170","doi-asserted-by":"crossref","first-page":"14","DOI":"10.18565\/cardio.2015.7.14-25","article-title":"First experience of clinical application of LCZ696\u2013an AT1-angiotensin receptors and Neprilysin inhibitor\u2013in patients with chronic heart failure and reduced ejection fraction","volume":"55","author":"Kobalava","year":"2015","journal-title":"Kardiologiia"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0175","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0180","doi-asserted-by":"crossref","first-page":"40","DOI":"10.15420\/cfr.2016:1:1","article-title":"The mechanism of action of LCZ696","volume":"2","author":"Menendez","year":"2016","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0185","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/ejhf.788","article-title":"What proportion of patients with chronic heart failure are eligible for sacubitril\u2013valsartan?","volume":"19","author":"Pellicori","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0190","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ejhf.548","article-title":"Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens","volume":"18","author":"Senni","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0195","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ijcard.2016.08.323","article-title":"Practical considerations on the introduction of sacubitril\/valsartan in clinical practice: current evidence and early experience","volume":"223","author":"Farmakis","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2018.03.093_bb0200","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ehf2.12246","article-title":"Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril\/valsartan","volume":"5","author":"Pascual-Figal","year":"2018","journal-title":"ESC Hear Fail"},{"key":"10.1016\/j.ijcard.2018.03.093_bb0205","unstructured":"Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI - ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02924727 (accessed February 8, 2018)."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318308660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318308660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T17:22:10Z","timestamp":1545931330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527318308660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":41,"alternative-id":["S0167527318308660"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.093","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of sacubitril\/valsartan on cardiac filling pressures in patients with left ventricular systolic dysfunction","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}